keyword
MENU ▼
Read by QxMD icon Read
search

breast cancer, metastatic, prognostic markers

keyword
https://www.readbyqxmd.com/read/27911856/splicing-factor-ratio-as-an-index-of-epithelial-mesenchymal-transition-and-tumor-aggressiveness-in-breast-cancer
#1
Pietro Fici, Giulia Gallerani, Anne-Pierre Morel, Laura Mercatali, Toni Ibrahim, Emanuela Scarpi, Dino Amadori, Alain Puisieux, Michel Rigaud, Francesco Fabbri
Epithelial-to-mesenchymal transition (EMT) has been shown to be associated with tumor progression and metastasis. During this process in breast cancer, a crucial role is played by alternative splicing systems. To identify a new early prognostic marker of metastasis, we evaluated EMT-related gene expression in breast cell lines, and in primary tumor tissue from 31 patients with early breast cancer, focusing our attention on EMT-related splicing factors ESRP1, ESRP2 and RBFOX2. Results showed that the expression patterns of these genes were indicative of the onset of EMT in in-vitro models, but not in tissue samples...
November 29, 2016: Oncotarget
https://www.readbyqxmd.com/read/27852262/e-cadherin-genetic-variants-predict-survival-outcome-in-breast-cancer-patients
#2
Hager Memni, Yosra Macherki, Zahra Klayech, Ahlem Ben-Haj-Ayed, Karim Farhat, Yassmine Remadi, Sallouha Gabbouj, Wijden Mahfoudh, Nadia Bouzid, Noureddine Bouaouina, Lotfi Chouchane, Abdelfattah Zakhama, Elham Hassen
BACKGROUND: E-cadherin is a major component of adherens junctions that regulates cell shape and maintains tissue integrity. A complete loss or any decrease in cell surface expression of E-cadherin will interfere with the cell-to-cell junctions' strength and leads to cell detachment and escape from the primary tumor site. In this prospective study, three functional single nucleotide polymorphisms (-347G/GA, rs5030625; -160C/A, rs16260; +54C/T, rs1801026), were found to modulate E-cadherin expression...
November 16, 2016: Journal of Translational Medicine
https://www.readbyqxmd.com/read/27768764/combination-of-cancer-stem-cell-markers-cd44-and-cd24-is-superior-to-aldh1-as-a-prognostic-indicator-in-breast-cancer-patients-with-distant-metastases
#3
Yoshiya Horimoto, Atsushi Arakawa, Noriko Sasahara, Masahiko Tanabe, Sei Sai, Takanori Himuro, Mitsue Saito
The combination of CD44 and CD24, or aldehyde dehydrogenase 1 (ALDH1) alone, is a widely used cancer stem cell marker in breast cancer. However, no conclusion has yet been reached as to which marker is the best for characterizing cancer stemness. Immunohistochemical evaluation using cancer stem cell markers is clearly less common clinically than in basic experiments and how the expressions of these markers relate to patient outcomes remains controversial. To investigate whether combining these markers might improve the prediction of patient outcomes, we immunohistochemically examined clinical samples...
2016: PloS One
https://www.readbyqxmd.com/read/27739521/label-free-enumeration-collection-and-downstream-cytological-and-cytogenetic-analysis-of-circulating-tumor-cells
#4
Manjima Dhar, Edward Pao, Corinne Renier, Derek E Go, James Che, Rosita Montoya, Rachel Conrad, Melissa Matsumoto, Kyra Heirich, Melanie Triboulet, Jianyu Rao, Stefanie S Jeffrey, Edward B Garon, Jonathan Goldman, Nagesh P Rao, Rajan Kulkarni, Elodie Sollier-Christen, Dino Di Carlo
Circulating tumor cells (CTCs) have a great potential as indicators of metastatic disease that may help physicians improve cancer prognostication, treatment and patient outcomes. Heterogeneous marker expression as well as the complexity of current antibody-based isolation and analysis systems highlights the need for alternative methods. In this work, we use a microfluidic Vortex device that can selectively isolate potential tumor cells from blood independent of cell surface expression. This system was adapted to interface with three protein-marker-free analysis techniques: (i) an in-flow automated image processing system to enumerate cells released, (ii) cytological analysis using Papanicolaou (Pap) staining and (iii) fluorescence in situ hybridization (FISH) targeting the ALK rearrangement...
October 14, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27660506/monitoring-metastasis-and-cachexia-in-a-patient-with-breast-cancer-a-case-study
#5
Nikita Consul, Xiaotao Guo, Courtney Coker, Sara Lopez-Pintado, Hanina Hibshoosh, Binsheng Zhao, Kevin Kalinsky, Swarnali Acharyya
Cachexia, a wasting syndrome associated with advanced cancer and metastasis, is rarely documented in breast cancer patients. However, the incidence of cachexia in breast cancer is now thought to be largely underestimated. In our case report of a breast cancer patient with bone metastasis monitored during the course of her treatment, we document the development of cachexia by image analysis in relation to her metastatic burden. Elucidation of the link between metastatic burden and cachexia could unveil a highly specific screening process for metastasis, by assessing true muscle mass loss...
2016: Clinical Medicine Insights. Oncology
https://www.readbyqxmd.com/read/27651430/tip60-inhibits-metastasis-by-ablating-dnmt1-snail2-driven-epithelial-mesenchymal-transition-program
#6
Yanzhou Zhang, Vanitha Krishna Subbaiah, Deepa Rajagopalan, Cheng Yong Tham, Lissa Nurrul Abdullah, Tan Boon Toh, Min Gong, Tuan Zea Tan, Shweta Pradip Jadhav, Amit Kumar Pandey, Neerja Karnani, Edward Kai-Hua Chow, Jean Paul Thiery, Sudhakar Jha
HIV-Tat-interacting protein of 60 kDa (TIP60) is a lysine acetyltransferase and known to be downregulated in multiple cancers. Among various signalling pathways, TIP60 is implicated in regulating epithelial-mesenchymal transition (EMT). Here, we show that TIP60 expression abrogates cell migration and metastatic potential of breast cancer cells using in vitro and in vivo models. Mechanistically, we show that this is through its ability to destabilize DNMT1 and inhibit SNAIL2 function (SNAIL2-mediated EMT/cell migration)...
September 20, 2016: Journal of Molecular Cell Biology
https://www.readbyqxmd.com/read/27621566/pancreatic-cancer-are-liquid-biopsies-ready-for-prime-time
#7
REVIEW
Alexandra R Lewis, Juan W Valle, Mairead G McNamara
Pancreatic cancer is a disease that carries a poor prognosis. Accurate tissue diagnosis is required. Tumours contain a high content of stromal tissue and therefore biopsies may be inconclusive. Circulating tumour cells (CTCs) have been investigated as a potential "liquid biopsy" in several malignancies and have proven to be of prognostic value in breast, prostate and colorectal cancers. They have been detected in patients with localised and metastatic pancreatic cancer with sensitivities ranging from 38%-100% using a variety of platforms...
August 28, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/27618787/her2-her3-dimer-quantification-by-flim-fret-predicts-breast-cancer-metastatic-relapse-independently-of-her2-ihc-status
#8
Gregory Weitsman, Paul R Barber, Lan K Nguyen, Katherine Lawler, Gargi Patel, Natalie Woodman, Muireann T Kelleher, Sarah E Pinder, Mark Rowley, Paul A Ellis, Anand D Purushotham, Anthonius C Coolen, Boris N Kholodenko, Borivoj Vojnovic, Cheryl Gillett, Tony Ng
Overexpression of HER2 is an important prognostic marker, and the only predictive biomarker of response to HER2-targeted therapies in invasive breast cancer. HER2-HER3 dimer has been shown to drive proliferation and tumor progression, and targeting of this dimer with pertuzumab alongside chemotherapy and trastuzumab, has shown significant clinical utility. The purpose of this study was to accurately quantify HER2-HER3 dimerisation in formalin fixed paraffin embedded (FFPE) breast cancer tissue as a novel prognostic biomarker...
July 13, 2016: Oncotarget
https://www.readbyqxmd.com/read/27602758/analysis-of-the-hormone-receptor-status-of-circulating-tumor-cell-subpopulations-based-on-epithelial-mesenchymal-transition-a-proof-of-principle-study-on-the-heterogeneity-of-circulating-tumor-cells
#9
Xiuwen Guan, Fei Ma, Suyan Liu, Shiyang Wu, Rong Xiao, Lifang Yuan, Xiaoying Sun, Zongbi Yi, Huiyi Yang, Binghe Xu
Although the enumeration of circulating tumor cells (CTCs) has been demonstrated to be a prognostic indicator in metastatic breast cancer, the heterogeneous characteristics of CTCs, such as variations in the epithelial-mesenchymal transition (EMT), may limit its broad clinical application. To investigate an uncomplicated and practicable detection approach based on the potential utility of the heterogeneity of CTCs from the standpoint of the EMT phenotype and ER/PR status of CTCs, an analysis was conducted using peripheral blood samples obtained from 28 metastatic breast cancer patients...
September 1, 2016: Oncotarget
https://www.readbyqxmd.com/read/27589561/periostin-is-identified-as-a-putative-metastatic-marker-in-breast-cancer-derived-exosomes
#10
Ioulia Vardaki, Sophia Ceder, Dorothea Rutishauser, George Baltatzis, Theodoros Foukakis, Theocharis Panaretakis
Breast cancer (BrCa) is the most frequent cancer type in women and a leading cause of cancer related deaths in the world. Despite the decrease in mortality due to better diagnostics and palliative care, there is a lack of prognostic markers of metastasis. Recently, the exploitation of liquid biopsies and in particular of the extracellular vesicles has shown promise in the identification of such prognostic markers. In this study we compared the proteomic content of exosomes derived from metastatic and non-metastatic human (MCF7 and MDA-MB-231) and mouse (67NR and 4T1) cell lines...
August 29, 2016: Oncotarget
https://www.readbyqxmd.com/read/27564096/comparative-metabolic-and-lipidomic-profiling-of-human-breast-cancer-cells-with-different-metastatic-potentials
#11
Hye Youn Kim, Kyung Min Lee, So Hyun Kim, Yeo Jung Kwon, Young Jin Chun, Hyung Kyoon Choi
This study conducted comprehensive and comparative metabolic and lipidomic profiling of a human epithelial breast cell line (MCF-10A), a slightly metastatic (MCF-7), and a highly metastatic (MDA-MB-231) breast cancer cell line using gas chromatography mass spectrometry (GC-MS) and direct infusion mass spectrometry (DI-MS). Among 39 metabolites identified by GC-MS analysis, xanthine, glucose-6-phosphate, mannose-6-phosphate, guanine, and adenine were selected as prognostic markers of breast cancer metastasis...
August 24, 2016: Oncotarget
https://www.readbyqxmd.com/read/27563810/efficacy-of-bortezomib-in-sarcomas-with-high-levels-of-map17-pdzk1ip1
#12
Marco Perez, Javier Peinado-Serrano, Jose Manuel Garcia-Heredia, Irene Felipe-Abrio, Cristina Tous, Irene Ferrer, Javier Martin-Broto, Carmen Saez, Amancio Carnero
Sarcomas are malignant tumors accounting for a high percentage of cancer morbidity and mortality in children and young adults. Surgery and radiation therapy are the accepted treatments for most sarcomas; however, patients with metastatic disease are treated with systemic chemotherapy. Many tumors display marginal levels of chemoresponsiveness, and new treatment approaches are needed. MAP17 is a small non-glycosylated membrane protein overexpressed in carcinomas. The levels of MAP17 could be used as a prognostic marker to predict the response to bortezomib in hematological malignancies and in breast tumors...
August 22, 2016: Oncotarget
https://www.readbyqxmd.com/read/27534575/n-telopeptide-of-type-i-collagen-long-term-dynamics-in-breast-cancer-patients-with-bone-metastases-clinical-outcomes-and-influence-of-extraskeletal-metastases
#13
Arlindo R Ferreira, Irina Alho, Ning Shan, Margarida Matias, Mariana Faria, Sandra Casimiro, Kim Leitzel, Suhail Ali, Allan Lipton, Luís Costa
BACKGROUND: Markers of bone metabolism, such as N-telopeptide of type I collagen (NTX), have been demonstrated to be prognostic in previous trials of breast cancer (BC) patients with bone metastases (BMs). In the present study, we tested the survival effect of the NTX response to zoledronic acid (ZA) at 3 and 12 months in a contemporaneous cohort of BC patients with BMs and evaluated the influence of extraskeletal metastatic disease on NTX variation. PATIENTS AND METHODS: The present study was a prospective cohort study of consecutive BC patients diagnosed and treated at a single center...
August 17, 2016: Oncologist
https://www.readbyqxmd.com/read/27521101/benchmarking-clinical-practice-quality-an-audit-of-ipsilateral-breast-tumor-recurrence-in-patients-managed-for-t1-t2-breast-carcinoma
#14
Clare Suttie, Michael Back, Jennifer Donovan, Milan Holecek, Marita Morgia, Lesley Guo, Gillian Lamoury
AIM: Breast conserving surgery and adjuvant radiotherapy has equivalent oncological outcomes to mastectomy and is the standard of care for treatment of early-stage invasive breast cancer. Auditing is an essential component of ongoing quality assurance and clinical governance. It also serves to identify patient and tumor factors that have prognostic and therapeutic implications. The aim of this paper is to report on the clinical audit of treatment outcomes for patients undergoing adjuvant radiation treatment for early breast cancer at the Northern Sydney Cancer Care Centre...
August 12, 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27509988/expression-levels-of-tetraspanin-kai1-cd82-in-breast-cancers-in-north-indian-females
#15
Richa Singh, Madan Lal Brahma Bhatt, Saurabh Pratap Singh, Vijay Kumar, Madhu Mati Goel, Durga Prasad Mishra, Kirti Srivastava, Rajendra Kumar
BACKGROUND: Carcinogenesis is a multifaceted intricate cellular mechanism of transformation of the normal functions of a cell into neoplastic alterations. Metastasis may result in failure of conventional treatment and death Hence, research on metastatic suppressors in cancer is a high priority. The metastatic suppressor gene CD82, also known as KAI1, is a member of the transmembrane 4 superfamily which was first identified in carcinoma of prostate. Little work has been done on this gene in breast cancer...
2016: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/27501846/nanoroughened-adhesion-based-capture-of-circulating-tumor-cells-with-heterogeneous-expression-and-metastatic-characteristics
#16
Weiqiang Chen, Steven G Allen, Ajaya Kumar Reka, Weiyi Qian, Shuo Han, Jianing Zhao, Liwei Bao, Venkateshwar G Keshamouni, Sofia D Merajver, Jianping Fu
BACKGROUND: Circulating tumor cells (CTCs) have shown prognostic relevance in many cancer types. However, the majority of current CTC capture methods rely on positive selection techniques that require a priori knowledge about the surface protein expression of disseminated CTCs, which are known to be a dynamic population. METHODS: We developed a microfluidic CTC capture chip that incorporated a nanoroughened glass substrate for capturing CTCs from blood samples. Our CTC capture chip utilized the differential adhesion preference of cancer cells to nanoroughened etched glass surfaces as compared to normal blood cells and thus did not depend on the physical size or surface protein expression of CTCs...
2016: BMC Cancer
https://www.readbyqxmd.com/read/27488299/molecular-markers-and-targeted-therapeutics-in-metastatic-tumors-of-the-spine-changing-the-treatment-paradigms
#17
C Rory Goodwin, Nancy Abu-Bonsrah, Laurence D Rhines, Jorrit-Jan Verlaan, Mark H Bilsky, Ilya Laufer, Stefano Boriani, Daniel M Sciubba, Chetan Bettegowda
STUDY TYPE: A review of the literature. OBJECTIVE: The aim of this study was to discuss the evolution of molecular signatures and the history and development of targeted therapeutics in metastatic tumor types affecting the spinal column. SUMMARY OF BACKGROUND DATA: Molecular characterization of metastatic spine tumors is expected to usher in a revolution in diagnostic and treatment paradigms. Molecular characterization will provide critical information that can be used for initial diagnosis, prognosticating the ideal treatment strategy, assessment of treatment efficacy, surveillance and monitoring recurrence, and predicting complications, clinical outcome, and overall survival in patients diagnosed with metastatic cancers to the spinal column...
October 15, 2016: Spine
https://www.readbyqxmd.com/read/27485113/identification-of-novel-biomarkers-associated-with-poor-patient-outcomes-in-invasive-breast-carcinoma
#18
Renata A Canevari, Fabio A Marchi, Maria A C Domingues, Victor Piana de Andrade, José R F Caldeira, Sergio Verjovski-Almeida, Silvia R Rogatto, Eduardo M Reis
Breast carcinoma (BC) corresponds to 23 % of all cancers in women, with 1.38 million new cases and 460,000 deaths worldwide annually. Despite the significant advances in the identification of molecular markers and different modalities of treatment for primary BC, the ability to predict its metastatic behavior is still limited. The purpose of this study was to identify novel molecular markers associated with distinct clinical outcomes in a Brazilian cohort of BC patients. We generated global gene expression profiles using tumor samples from 24 patients with invasive ductal BC who were followed for at least 5 years, including a group of 15 patients with favorable outcomes and another with nine patients who developed metastasis...
August 2, 2016: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/27466531/ovarian-metastases-from-breast-cancer-a-series-of-28-cases
#19
Celine Pimentel, Margaux Becquet, Vincent Lavoue, Sebastien Henno, Jean Leveque, Lobna Ouldamer
BACKGROUND/AIM: Ovarian metastases from breast cancer present diagnostic and therapeutic challenges. We conducted a two-center retrospective study to analyze the characteristics and evolution of patients with histologically proven ovarian metastases from breast cancer. PATIENTS AND METHODS: The records of 28 patients were analyzed, taking into consideration clinical and biological characteristics of primary breast tumors and ovarian metastases. Moreover, the outcomes of patients after diagnosis of metastases were analyzed by comparing two patient groups defined by whether the surgical treatment of ovarian metastases was optimal (residual tumor <2 cm) or not (residual tumor >2 cm)...
August 2016: Anticancer Research
https://www.readbyqxmd.com/read/27464303/serum-nse-mmp-9-and-her2-extracellular-domain-are-associated-with-brain-metastases-in-metastatic-breast-cancer-patients-predictive-biomarkers-for-brain-metastases
#20
Amélie Darlix, Pierre-Jean Lamy, Evelyne Lopez-Crapez, Antoine Laurent Braccini, Nelly Firmin, Gilles Romieu, Simon Thézenas, William Jacot
Breast cancer (BC) is the second most common cause of brain metastases (BM). Predictive factors for BM have been widely studied in metastatic BC; however, there is no known serum tumor marker to accurately predict BM. Elevated serum S100ß protein and neuron-specific enolase (NSE) could reflect the brain damages induced by BM. Matrix metalloproteinase 9 (MMP-9) is involved in tumor invasion and metastatic dissemination, including BM. Also, HER2-amplified BC were shown to have a particular tropism for central nervous system (CNS)...
November 15, 2016: International Journal of Cancer. Journal International du Cancer
keyword
keyword
80880
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"